Skip to content
10-K/A

Annual Report

CYCLERION THERAPEUTICS, INC. CYCN

0001193125-25-277621

← back to feed
Filed
Nov 12, 2025 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 28, 2025 2.71M sh
Shares Diluted FY 2024 · Dec 31, 2024 2.52M sh
Shares Diluted FY 2024 · Dec 31, 2023 2.34M sh
Operating Cash Flow FY 2024 · Dec 31, 2024 −$4.33M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$21.25M
Cash And Equivalents FY 2024 · Dec 31, 2024 $3.23M
Cash And Equivalents FY 2024 · Dec 31, 2023 $7.57M
Stockholders Equity FY 2024 · Dec 31, 2024 $8.85M
Stockholders Equity FY 2024 · Dec 31, 2023 $11.29M
Current Liabilities FY 2024 · Dec 31, 2024 $725K
Current Liabilities FY 2024 · Dec 31, 2023 $2.09M
Current Assets FY 2024 · Dec 31, 2024 $4.23M
Current Assets FY 2024 · Dec 31, 2023 $8.02M
Total Assets FY 2024 · Dec 31, 2024 $9.58M
Total Assets FY 2024 · Dec 31, 2023 $13.37M
Eps Diluted FY 2024 · Dec 31, 2024 −$1.21
Eps Diluted FY 2024 · Dec 31, 2023 −$2.25
Eps Basic FY 2024 · Dec 31, 2024 −$1.21
Eps Basic FY 2024 · Dec 31, 2023 −$2.25
Sga Expense FY 2024 · Dec 31, 2024 $5.34M
Sga Expense FY 2024 · Dec 31, 2023 $8.13M
Rd Expense FY 2024 · Dec 31, 2024 $286K
Rd Expense FY 2024 · Dec 31, 2023 $1.52M
Net Income FY 2024 · Dec 31, 2024 −$3.06M
Net Income FY 2024 · Dec 31, 2023 −$5.26M
Operating Income FY 2024 · Dec 31, 2024 −$3.63M
Operating Income FY 2024 · Dec 31, 2023 −$12.95M